State Board of Administration of Florida Retirement System trimmed its position in shares of Aemetis, Inc. (NASDAQ:AMTX – Get Rating) by 18.3% in the fourth quarter, HoldingsChannel.com reports. The fund owned 14,078 shares of the specialty chemicals company’s stock after selling 3,160 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Aemetis were worth $56,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of AMTX. Tower Research Capital LLC TRC boosted its holdings in Aemetis by 173.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 5,586 shares of the specialty chemicals company’s stock valued at $34,000 after acquiring an additional 3,545 shares during the period. BNP Paribas Arbitrage SA raised its position in Aemetis by 105.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,517 shares of the specialty chemicals company’s stock valued at $47,000 after purchasing an additional 4,887 shares in the last quarter. Chapin Davis Inc. acquired a new stake in Aemetis in the 4th quarter valued at about $63,000. Prudential Financial Inc. acquired a new stake in Aemetis in the 2nd quarter valued at about $67,000. Finally, Occudo Quantitative Strategies LP acquired a new stake in Aemetis in the 2nd quarter valued at about $75,000. 50.72% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on AMTX shares. Piper Sandler began coverage on Aemetis in a research report on Monday, February 27th. They set an “underweight” rating and a $3.00 target price on the stock. Stifel Nicolaus lifted their price target on Aemetis from $9.00 to $9.80 in a research report on Friday, May 19th. Finally, Truist Financial cut their price target on Aemetis from $5.00 to $2.50 and set a “hold” rating on the stock in a research report on Thursday, April 13th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $12.09.
Aemetis Trading Down 2.1 %
Aemetis (NASDAQ:AMTX – Get Rating) last posted its quarterly earnings results on Thursday, March 9th. The specialty chemicals company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.29). The company had revenue of $66.73 million during the quarter, compared to analysts’ expectations of $74.82 million. As a group, equities analysts predict that Aemetis, Inc. will post -1.1 earnings per share for the current fiscal year.
Aemetis Company Profile
Aemetis, Inc is a renewable fuels and biochemical company, which engages in the acquisition, development, and commercialization of technologies that replace traditional petroleum-based products. It operates through the North America and India geographical segments. The North America segment manages Keyes Plant in California, the cellulosic ethanol facility in Riverbank, the cluster of biogas digesters on dairies near Keyes, California, the Goodland Plant, Kansas and the research and development facility in Minnesota.
- Get a free copy of the StockNews.com research report on Aemetis (AMTX)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Want to see what other hedge funds are holding AMTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aemetis, Inc. (NASDAQ:AMTX – Get Rating).
Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.